National Cancer Centre Singapore shared on LinkedIn:
“Major moment for NCCS lung cancer research!
Prof Daniel SW Tan presented at the Presidential Symposium of the 2026 World Conference on Lung Cancer in Seoul, South Korea today, sharing positive phase 3 results for zipalertinib (a novel EGFR inhibitor) in the treatment of EGFR exon 20 insertion non-small cell lung cancer, a subtype with historically limited treatment options.
The trial showed that patients lived significantly longer without disease progression when zipalertinib was added to chemotherapy (14.5 vs 8.5 months).
Proud of this milestone and excited for what it means for patients facing this challenging diagnosis.
More on the Symposium.”
You can also read: WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New Therapeutic Era
